GNPX News & Events

Genprex announced that The Canadian Intellectual Property Office has issued a Notice of Allowance to Genprex for a patent covering the use of Reqorsa Gene Therapy in combination with either PD-1 or PD-L1 antibodies for the treatment of both non-small cell lung cancer and small cell lung cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 and PD-L1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Chile, China, Singapore Europe, Korea, Australia and Israel.

Genprex files $250M mixed securities shelf

Genprex's research collaborators presented positive preclinical data on the company's diabetes gene therapy drug candidate at the 2026 American Society of Gene and Cell Therapy Annual Meeting. The collaborators presented preclinical data demonstrating that the diabetes gene therapy can reverse hyperglycemia in Type 2 diabetic mouse models. At two and/or four weeks after surgery, researchers performed intraperitoneal glucose tolerance testing or IPGTT, insulin tolerance testing or ITT, glucose-stimulated insulin secretion or GSIS, calculated HOMA-IR and assessed glucagon secretion. The results at four weeks showed major improvements in the control of diabetes. At four weeks after surgery, ex-vivo glucose-stimulated insulin secretion showed that islets isolated from HFD+CMV-PM-GFP treated mice had insulin secretion similar to islets from RD mice, and both groups had increased insulin secretion compared to islets from the control HFD groups, indicating improved beta-cell function with PM treatment. PM gene therapy reverses hyperglycemia, likely in large part by specifically enhancing beta-cell function and maturation. This approach is technically translatable to humans using endoscopic retrograde cholangiopancreatography to deliver PM gene therapy to the pancreas.

Genprex announced that The Israel Patent Office has granted Genprex a patent covering the use of Reqorsa Gene Therapy in combination with PD-1 antibodies for the treatment of cancer. This patent will expand on the previously granted patents for REQORSA in combination with PD-1 antibodies, which have been granted in the U.S., Japan, Mexico, Russia, Australia, Chile, China, Singapore and Europe.